A novel therapeutic principle is aimed at controlling the airway inflammation in allergic asthma, to mitigate the course of the disease. With its comprehensive expertise, Fraunhofer ITEM successfully performed toxicology testing of the novel DNAzyme-based drug developed by sterna biologicals GmbH & Co. KG and also part of the clinical trials. The results of the proof-of-concept study in man have now been published in the renowned “New England Journal of Medicine”.
Asthma is a highly prevalent airway disease, affecting an estimated 300 million people worldwide. Asthmatics suffer not only from the disease itself, but also from its wide-ranging consequences. The therapeutic options for severe asthma to date are little satisfactory and require a new therapeutic principle. This is what sterna biologicals has developed with the new drug “SB010”.
It is based on inhibiting the transcription factor GATA-3 by a so-called DNAzyme – a synthetic DNA molecule with enzymatic action for inhaled administration. It binds to the transcription factor that triggers the inflammatory response and thus the typical asthma symptoms, inactivating it by enzymatic cleavage.
The Fraunhofer ITEM has accompanied development of this first-in-class antagonist with its expertise, from scientific advice and the required toxicity tests (in cooperation with Nycomed GmbH) to clinical trials of phases Ib and IIa. The latter, i.e. the proof-of-concept study, was conducted as a multi-center study in seven German centers under the scientific direction of Professor Norbert Krug, Fraunhofer ITEM Medical Director.
In the randomized, double-blind, parallel-group, multi-center trial, efficacy of the new therapeutic agent was tested. Treatment with “SB010” over 28 days significantly improved lung function after specific allergen challenge as compared to placebo. “SB010” furthermore proved to be safe and well tolerated. The results of this study were presented during this year’s International Conference of the American Thoracic Society in Denver, USA.
“Recent research indicates that approximately 50 percent of all asthmatics suffer from allergic asthma. This type of asthma is Th2-driven across all levels of disease severity. Therefore, developing novel therapeutics specifically for this group of patients holds great promise, in particular of drugs for inhaled delivery. Further clinical trials with ‘SB010’ in a larger cohort of asthmatics are thus warranted,” explains Krug.
Prof. Dr. Norbert Krug; +49 511 5350-8100
Dr. Cathrin Nastevska; +49 511 5350-225
The text of this press release including an image for download can be found on our homepage at http://www.item.fraunhofer.de/en/press-media/latest-news/pm_sternaSB010.html
Kommunikation | Fraunhofer-Gesellschaft
Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg
Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy